Savara (SVRA) Cash & Equivalents (2010 - 2026)
Savara's (SVRA) quarterly Cash & Equivalents came in at $38.8 million in Q1 2026, up 97.96% year-on-year from $19.6 million in Q1 2025, and up 16.94% on a QoQ basis from $33.2 million in Q4 2025.
Savara (SVRA) Cash & Equivalents (2010 - 2026) Analysis & Trends
Savara (SVRA) has 17 years of Cash & Equivalents data on file, last reported at $38.8 million in Q1 2026.
- On a quarterly basis, Cash & Equivalents rose 97.96% year-over-year to $38.8 million in Q1 2026; TTM through Mar 2026 was $38.8 million, a 97.96% increase from a year earlier, with the FY2025 full-year figure at $33.2 million, up 119.33% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $38.8 million, up from $33.2 million in the prior quarter.
- Over the last five years, Cash & Equivalents for SVRA reached as high as $119.8 million in Q3 2022 and fell as low as $15.1 million in Q4 2024.
- Historically, Cash & Equivalents has averaged $38.8 million across 5 years, with a median of $26.6 million in 2023.
- Across the five-year window, Cash & Equivalents jumped 168.01% in 2022 and tumbled 76.88% in 2023, its largest moves.
- Year by year, Cash & Equivalents stood at $52.1 million in 2022, then slumped by 48.97% to $26.6 million in 2023, then plunged by 43.1% to $15.1 million in 2024, then surged by 119.33% to $33.2 million in 2025, then climbed by 16.94% to $38.8 million in 2026.
- Per Business Quant data, the three most recent Cash & Equivalents figures were $38.8 million in Q1 2026, $33.2 million in Q4 2025, and $16.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 82.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.49 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.96 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 3.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 440.94 Mn |
| 10 | Savara | 1.24 Bn | 1.24 Bn | - | 38.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.80 Mn |
| Dec 31, 2025 | 33.18 Mn |
| Sep 30, 2025 | 16.28 Mn |
| Jun 30, 2025 | 17.40 Mn |
| Mar 31, 2025 | 19.60 Mn |
| Dec 31, 2024 | 15.13 Mn |
| Sep 30, 2024 | 21.43 Mn |
| Jun 30, 2024 | 23.90 Mn |
| Mar 31, 2024 | 16.80 Mn |
| Dec 31, 2023 | 26.59 Mn |
| Sep 30, 2023 | 27.70 Mn |
| Jun 30, 2023 | 22.70 Mn |
| Mar 31, 2023 | 34.00 Mn |
| Dec 31, 2022 | 52.10 Mn |
| Sep 30, 2022 | 119.80 Mn |
| Jun 30, 2022 | 95.15 Mn |
| Mar 31, 2022 | 79.23 Mn |
| Dec 31, 2021 | 34.01 Mn |
| Sep 30, 2021 | 44.70 Mn |
| Jun 30, 2021 | 40.65 Mn |